Work

Abstract CT222: Differences in pharmacokinetics of TRC105 (anti-endoglin antibody) when administered as a single agent versus in combination with bevacizumab (Bev)

Year: 2014

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2014-ct222

Authors: Shawn D. Spencer, Lee S. Rosen, Michael S. Gordon, Francisco Robert, Daniela Matei, Cody J. Peer, Bonne Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, W. Douglas Figg

Institutions: Fairleigh Dickinson University, University of California, Los Angeles, Pinnacle Oncology Hematology, University of Alabama at Birmingham, Indiana University Indianapolis, National Cancer Institute, Tracon Pharmaceuticals (United States), Roswell Park Comprehensive Cancer Center

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1996168722

Cites:

Cited by:

Related to: 10